S Berberich, New Front Launched in War on Malaria , Business Gazette, October, 2007
> Download PDF
Staff Writer, Whole Parasite Malaria Vaccine to be Manufactured for Clinical Trials, News-Medical.Net, October, 2007
> Download PDF
Staff Writer, Researchers Aim to Use Mosquitoes to Bite Back at Malaria, Economic Times, October, 2007
> Download PDF
M Fox, Malaria Vaccine Plant Takes a Gamble, Reuters Africa, October, 2007
> Download PDF
B Shore, Bush Recognizes Social Entrepreneurship, Seattle Post-Intelligencer, January, 2007
> Download PDF
S Berberich, $29.3M Gates Grant Boosts Sanaria, Business Gazette, December, 2006
> Download PDF
A Coghlan, Mosquito 'Factories' to Fight Malaria, New Scientist, December, 2006
> Download PDF
G Taubes, An Interview With Dr. Stephen Hoffman , Essential Science Indicators: Special Topics, May, 2006
> Download PDF
N Adler, A Conversation With Stephen Hoffman, Washington Business Journal, March, 2006
> Download PDF
M Myers, The Malaria Fighter, Business 2.0, Jan/Feb 2006
> Download PDF
S Berberich, Sanaria to Test Malaria Vaccine, Business Gazette, January, 2006
> Download PDF
N Adler, Sanaria Gets $4M in Gov't Funds For Malaria Vaccine, Washington Business Journal, June, 2005
> Download PDF
D Butler, Mosquito Production Mooted as Fast Track to Malaria Vaccine, Nature, 2003
> Download PDF
PRESS RELEASES
February 23, 2010: Sanaria Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research grant to develop a genetically attenuated whole parasite malaria vaccine > Download PDF
February 19, 2010: Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria's PfSPZ vaccine > Download PDF
September 16, 2009: Sanaria receives multi-year U.S. NIH phase II Small Business Innovation Research grant to enhance efficiency and scale-up of its malaria vaccine manufacturing process > Download PDF
June 2, 2009: Sanaria receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech > Download PDF
April 23, 2009: Sanaria and PATH-MVI announce that Phase 1 trial of Sanaria's whole-parasite malaria vaccine called PfSPZ Vaccine to begin; FDA approval for testing in humans watershed moment for unique malaria vaccine approach > Download PDF
October 30, 2008: Sanaria and TI Pharma collaborators at Radboud University Nijmegen Medical Centre and Leiden University Medical Centre publish the first report of genetically attenuated P. falciparum sporozoites > Download PDF
July 29, 2008: Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant > Download PDF
May 15, 2008: Sanaria named Maryland's Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration > Download PDF
January 16, 2008: Sanaria, Top Institute Pharma, Radboud University Nijmegen Medical Centre and Leiden University Medical Center enter into $23.6 million research agreement
> Download PDF
October 26, 2007: Sanaria, PATH Malaria Vaccine Initiative Open Manufacturing Facility For Producing World's First "Whole-Parasite" Malaria Vaccine
> Download PDF
January 29, 2007: Sanaria Inc. Receives Multi-Year $3.47 Million U.S. NIH Phase I and Phase II Small Business Innovation Research Grants to Enhance Development of its Malaria Vaccine
> Download PDF
December 14, 2006: PATH Malaria Vaccine Initiative Announces New Partnership To Accelerate Development of Novel Malaria Vaccine Candidate MVI and Sanaria Inc. to Conduct Initial Safety and Test-of-Concept Trial
> Download PDF
March 19, 2006: Sanaria CEO, Dr. Stephen L. Hoffman, is the most cited author in the world
> Download PDF
June 20, 2005: Sanaria Receives NIAID (NIH) award for Development of its Malaria Vaccine
> Download PDF
May 2, 2005: Sanaria Receives U.S. Army Award for Development of its Malaria Vaccine
> Download PDF
October 20, 2004: Dr. Stephen L. Hoffman Elected to Membership in the Institute of Medicine of National Academies
> Download PDF
July 13, 2004: The Institute for One World Health and Sanaria
> Download PDF
RELEVANT PUBLICATIONS
TC Luke and SL Hoffman, Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine, Journal of Experimental Biology, 2003
> Download PDF
SL Hoffman et al., Protection of Humans against Malaria by Immunization with Radiation-Attenuated Plasmodium falciparum Sporozoites, Journal of Infectious Diseases, 2002
> Download PDF
BCL van Schaijk et al., Gene Disruption of Plasmodium falciparum p52 Results in Attenuation of Malaria Liver Stage Development in Cultured Primary Human Hepatocytes, PloS ONE, 2008
> Download PDF
R Chattopadhyay, S Conteh, M Li, E James, J Epstein, SL Hoffman, The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine, Vaccine, 2009
> Download PDF
C Plowe, P Alonso, SL Hoffman, The Potential Role of Vaccines in the Elimination of Falciparum Malaria and the Eventual Eradication
of Malaria, The Journal of Infectious Disease, 2009
> Download PDF
S Conteh, R Chattopadhyay, C Anderson, SL Hoffman, Plasmodium yoelii-Infected A. stephensi Inefficiently
Transmit Malaria Compared to Intravenous Route, PLoS One, 2010
> Download PDF
SL Hoffman et al, Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria, Human Vaccines, 2010
> Download PDF
NEWS
Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Esquire magazine
> December 2008
Sanaria and TI Pharma collaborators publish the first report of genetically attenuated P. falciparum sporozoites; PLoS ONE; Press Release
> July 2008
Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant Press Release
> July 2008
Sanaria announced that Adel A. F. Mahmoud, M.D., Ph.D, of the Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University and former President of Merck Vaccines, was elected to Sanaria's Board of Directors
> November 2007
Sanaria signs agreement with University of Maryland Biotechnology Institute
> June 2007
Sanaria finalizes agreement with Columbia University to develop genetically attenuated malaria sporozoite vaccine
> May 2007
Sanaria receives Phase I SBIR grant from NIAID, NIH
> April 2007
PATH-Malaria Vaccine Initiative receives $29.3M from the Bill and Melinda Gates Foundation to support Sanaria’s malaria vaccine development efforts
> November 2006
Sanaria CEO receives award for malariology from American Society of Tropical Medicine and Hygiene
> November 2006
Sanaria CEO receives honorary doctoral degree from Monmouth University
> October 2006
Sanaria receives Phase II SBIR grant from NIAID, NIH
> September 2006
